Targeting galectin-9 in obesity-related chemoresistance

Researchers studying the impact of obesity on leukemia have identified galectin-9 as an important immunotherapeutic target to overcome obesity-induced chemoresistance, publishing their findings in Nature Communications. CB faculty member Curtis J. Henry, assistant professor of pediatrics and an investigator with the Aflac Cancer and Blood Disorders Center and Winship Cancer Institute of Emory University, is the study’s senior author.

Galectin-9 is a protein expressed on the surface of leukemia cells that promotes chemoresistance, and adipocytes secrete factors that promote greater levels of galectin-9. Antibody-mediated targeting of galectin-9 can significantly extend the survival of obese but not lean mice with aggressive B-acute lymphoblastic leukemia, the authors report.

Latest News Stories